Organisation

The CoCA project is governed by the following consortium/decision-making bodies. Please click on each body for more details:

Coordinator and Project Office

PROJECT COORDINATOR

The Coordinator of CoCA is Prof. Dr. Andreas Reif, Chair of the Department of Psychiatry, Psychosomatic Medicine and Psychotherapy at the University Hospital Frankfurt in Germany.

As the project coordinator he is the legal entity acting as the intermediary between the European Commission and the consortium as well as the supervisor of the overall progress of the project.

GUFa_Andreas Reif_large
Prof. Andreas Reif

University Hospital of Frankfurt (GUF)

Phone:+49 (0)69 6301 5222
Fax:+49 (0)69 6301 3839

Send message

PROJECT MANAGEMENT OFFICE (PMO)

The project management office is located both at concentris in Fürstenfeldbruck and with the Coordinator in Frankfurt. While the Coordinator is mainly dealing with the scientific management, concentris is taking care of the administrative, financial and contractual management and other organisational tasks.

The PMO is the central node of communication for CoCA and is responsible for the day-to-day management of the project. It acts as a help-desk for all beneficiaries and supports the Coordinator, the General Assembly and the Steering Committee in fulfilling their tasks and the execution of decisions.

The project manager at concentris for CoCA is Dr. Cora Meyer.

Concentris--Cora-Meyer
Dr. Cora Meyer

concentris research management GmbH

Project manager CoCA

Phone:+49 8141 6252 8574
Fax:+49 8141 6252 8577

Send message

Steering Committee (SC)

The Steering Committee (SC) consists of all WP leaders and a representative at concentris and meets twice a year. It is the supervisory body where all technical details of the work are discussed. It is responsible for the successful implementation of the project regarding its schedule, budget and expected scientific quality. The SC is furthermore in charge of the preparation and execution of the decisions of the General Assembly.

  1. Catharina Hartman, Professor, Department of Psychiatry, University Medical Center Groningen, Netherlands
  2. Bru Cormand, Professor, Academic Secretary of the Dept. of Genetics, University of Barcelona, Spain
  3. Johannes Thome, Professor, Chair of Dept. of the Clinic and Policlinic of Psychiatry and Psychotherapy, University Medicine Rostock, Germany
  4. Andreas Reif, Professor, Chair of Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Germany
  5. Ulrich Ebner-Priemer, Professor, Chair of Applied Psychology, Karlsruhe Institute of Technology, Germany
  6. Christine Freitag, Professor, Chair of Dept. of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Germany
  7. Jan Haavik, Professor, Head of Research Centre, Department of Biomedicine, University of Bergen, Norway
  8. Stephen Faraone, Professor, Distinguished Professor, Director of the Dept. of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, US
  9. Barbara Franke, Professor, Head of the Research lab for Multifactorial Diseases at the department of Human Genetics, Radboud University Medical Centre, Netherlands
  10. Jonna Kuntsi, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK
  11. concentris representative: Cora Meyer, Dr., concentris research management, Germany

General Assembly (GA)

The GA is the ultimate decision-making body of the Consortium and meets once a year. It consists of one representative of each partner and two of the coordinator with authority to vote, as well as a number of non-voting researchers and graduate students working for CoCA. The GA receives regularly status updates from all work packages, provides scientific and political directions and settles any dispute that might occur. It decides upon all issues involving changes to the content of the project, finances and intellectual property rights. It is in charge of making decisions of major and strategic relevance, either on its own initiative or as proposed by any of the partners or the Steering Committee.

INTERNAL ETHICS BOARD (IEB)

The internal ethics board is a consultative body, which is formed to ensure and improve the ethical components within CoCA. The members of the internal ethics board will be present at the annual GA meetings and will consider and mention any ethical issues which might require (stronger) attention within CoCA.

  1. Andreas Reif , Professor, Chair of Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Germany
  2. Christine Freitag, Professor, Chair of Dept. of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Germany
  3. Jan Buitelaar, Professor of Psychiatry and Child and Adolescent Psychiatry, Radbound University Medical Center, Netherlands
  4. Johannes Thome,  Professor, Chair of Dept. of the Clinic and Policlinic of Psychiatry and Psychotherapy, University Medicine Rostock, Germany
  5. Jonna Kuntsi,  Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK
  6. Jaanus Harro,   Professor, Head of Division of Neuropsychopharmacology, University of Tartu, Estonia
  7. Anders Børglum,  Professor, Director of Centre for Integrative Sequencing, Aarhus University

Independent Ethics Advisor Michael Kölch

Department of Child and Adolescent Psychiatry

Phone:-
Fax:-

Scientific and Ethical Advisory Board (SEAB)

The SEAB is a consultative body, which is formed to ensure and improve the scientific performance and the quality of results of CoCA. The members of the SEAB will be invited to the annual GA meetings in order to monitor the progress of work, to assess the scientific quality and to give feed-back to the Consortium members. The SEAB will also consider and mention any ethical issues which might require (stronger) attention in their feed-back. It has an independent advisory position that includes possible reporting of critical issues the EC, so that safeguarding of the project is ensured.

SEAB_Johannes Hebebrand
Prof. Johannes Hebebrand

Director of the Department of Child and Adolescent Psychiatry and Psychotherapy University of Duisburg-Essen, Germany

Phone:-
Fax:-

SEAB_Peter McGuffin
Prof. Peter McGuffin

Institute of Psychiatry, Psychology and Neuroscience King’s College London, UK

Phone:-
Fax:-

SEAB_James Swanson
Prof. James Swanson

Director of the Child Development Center, Pediatrics School of Medicine University of California, USA

Phone:
Fax:-

SEAB_Luis Rhode
Prof. Luis Rohde

President World Federation of AHDH, Department of Psychiatry, Federal University of Rio Grando do Sul, Brazil

Phone:
Fax:-

SEAB_Andrea Bilbow
Andrea Bilbow

President ADHD Europe (patient organization) UK

Phone:
Fax:-

Data and Safety Monitoring Committee (DSMC)

The DSMC will review any issues concerning the safety of the trial participants (by reviewing serious adverse events) as well as the integrity of the data and possible statistical problems such as selection bias, cross-over, failure to diagnose, failure to treat or failure to follow-up. The DSMC will meet once a year and advise the Steering Committee and the Coordinator/WP leader of the clinical trial on any critical issue.

DSMC_Michael Rösler
Michael Rösler

Professor,Director of the Institute of Forensic Psychiatry and Psychology, University of Saarland, Germany

Phone:
Fax:-

DSMC_Wolfgang Retz
Wolfgang Retz

Professor, Department of Psychiatry University of Mainz, Germany

Phone:
Fax:-

DSMC_Peter Schlattmann
Peter Schlattmann

1. Professor, Institute of Medical Statistics, Computer Sciences and Documentation, University of Jena, Germany

Phone:
Fax:-

Impact Board (IB)

The Impact Board is responsible for designing a structured communication plan for dissemination and the exploitation of program results and will monitor the steps being taken. Together with the Project Management Office it will oversee the comprehensive internal and external dissemination of project results and knowledge.

  1. Barbara Franke, Professor, Head of the Researchlab for Multifactorial Diseases at the department of Human Genetics, Radboud University Medical Centre, Netherlands
  2. Andreas Reif, Professor, Chair of Dept. of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Germany
  3. Catharina Hartman, Professor, Department of Psychiatry, University Medical Center Groningen, Netherlands
  4. Ulrich Ebner-Priemer, Professor, Chair of Applied Psychology, Karlsruhe Institute of Technology, Germany
  5. Stephen Faraone, Professor, Distinguished Professor, Director of the Dept. of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University
  6. Christine Freitag, Professor, Chair of Dept. of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, Germany
  7. Jan Haavik, Professor, Head of Research Centre, Department of Biomedicine, University of Bergen, Norway
  8. Philip Asherson, Professor, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK
  9. Christoph Bischoff-Everding, Dr, CEO, HGC GesundheitsColsult GmbH, Germany
  10. Junior’s representative: Adrian Muntaner, Dr., Faculty of Sport Sciences and Research Institute of Sports and Health, University of Granada, Spain
  11. Junior’s representative: Anna Rommel, Dr., Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK
  12. concentris representative: Cora Meyer, Dr., concentris research management, Germany

SEAB_Andrea Bilbow
External member: Andrea Bilbow

President ADHD Europe (patient organization) UK

Phone:-
Fax:-


Gain insight into the mechanisms underlying this comorbidity triad with its huge burden for healthcare, economy, and society